Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech Q3 revenue rises to $83.8 million; net income falls to $27.2 million

Mixed Impact 3 of 5 earnings Written later

Krystal Biotech reported third-quarter 2024 net product revenue of $83.8 million, up from $8.6 million a year earlier, driven by VYJUVEK sales. Net income fell to $27.2 million, or $0.91 per diluted share, from $80.7 million, or $2.79 per diluted share, a year earlier; that period included a $100 million gain on the sale of a priority review voucher, and this quarter included a $12.5 million litigation settlement charge. The company also set full-year 2024 non-GAAP R&D and SG&A expense guidance of $115 million to $125 million.

Key points

  • Q3 2024 net product revenue was $83.8 million versus $8.6 million in Q3 2023; gross margin for VYJUVEK was 92% for the quarter.
  • Q3 2024 net income was $27.2 million, or $0.91 per diluted share, compared with $80.7 million, or $2.79 per diluted share, in Q3 2023.
  • Q3 2024 included a $12.5 million litigation settlement expense and $100 million gain from a priority review voucher sale was recorded in Q3 2023.
  • Cash, cash equivalents and investments totaled $694.2 million as of September 30, 2024; full-year 2024 non-GAAP R&D and SG&A guidance is $115 million to $125 million.

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECNov 4, 2024, 8:04 AM ET
Accession number0001711279-24-000055

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.